This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used ...
In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more ...
The test, developed by Astrin Biosciences, utilizes deep proteomic profiling and a machine learning classifier to identify ...
Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...
The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
Apollo Cancer Centre successfully treats a 23-year-old's decade-long seizures using advanced, incision-free CyberKnife radiosurgery.
CBD and THC kill ovarian cancer cells at doses that largely spare normal cells, disrupting survival pathways through multiple ...
Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.
Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?
A combination of two cannabis-derived compounds can target ovarian cancer cells while sparing healthy cells, offering early clues toward new treatment possibilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback